<SEC-DOCUMENT>0001144204-18-066400.txt : 20181227
<SEC-HEADER>0001144204-18-066400.hdr.sgml : 20181227
<ACCEPTANCE-DATETIME>20181227161553
ACCESSION NUMBER:		0001144204-18-066400
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181226
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181227
DATE AS OF CHANGE:		20181227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		181254870

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv509972_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
December 26, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Applied
DNA Sciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(State or other jurisdiction<BR>
        of incorporation)</P></TD>
    <TD STYLE="width: 38%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><B>001-36745</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="width: 31%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><B>59-2262718</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>50 Health Sciences Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stony Brook, New York 11790</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices;
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>631-240-8800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 95%; padding-right: 2pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging growth company
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 7.01.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation FD Disclosure</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 26, 2018, Applied DNA Sciences, Inc. (&ldquo;Applied
DNA Sciences&rdquo; or the &ldquo;Company&rdquo;) closed its previously-announced underwritten public offering (the &ldquo;Offering&rdquo;)
of an aggregate of 5,500,000 shares of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), together with
warrants to purchase an aggregate of 5,500,000 shares of common stock (the &ldquo;Warrants&rdquo;) at an exercise price equal to
$0.50 per share of Common Stock with Maxim Group LLC (&ldquo;Maxim&rdquo;), as the sole underwriter and book running manager. Maxim
partially exercised its overallotment option that was granted pursuant to the Offering and purchased an additional 800,000 Warrants
at a price of $0.0000001 per Warrant. Such exercised portion of the overallotment also closed on December 26, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s press release, dated December 27, 2018,
announcing the closing of the offering is attached as Exhibit 99.1, to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information furnished pursuant to this Item 7.01, shall
not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference
into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by
specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>(d) Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="tv509972_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1 Press Release dated December 27, 2018</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 27, 2018</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLIED DNA SCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-right: 2pt; padding-left: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv509972_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Applied DNA Announces Closing of $2.75
Million<BR>
Public Offering of Common Stock and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>STONY BROOK, N.Y</B>. &ndash; December 27, 2018 &ndash;
Applied DNA Sciences, Inc. (NASDAQ: APDN) (&ldquo;Applied DNA&rdquo; or the &quot;Company&quot;), a leader in large-scale
PCR-based DNA manufacturing, <FONT STYLE="background-color: white">announced today that on December 26, 2018 </FONT>it closed
its previously announced underwritten public offering (the &ldquo;Offering&rdquo;) of an aggregate of 5,500,000 shares of
common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), together with warrants to purchase an aggregate of
5,500,000 shares of common stock (the &ldquo;Warrants&rdquo;) at an exercise price equal to $0.50 per share of Common Stock
with Maxim Group LLC (&ldquo;Maxim&rdquo;), as the sole underwriter and book running manager. Maxim partially exercised its
overallotment option that was granted pursuant to the Offering and purchased an additional 800,000 Warrants. Such exercised
portion of the overallotment also closed on December 26, 2018. The gross proceeds from the offering, before deducting the
underwriting discounts and commissions and estimated offering expenses payable by the Company, are $2.75
million.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Applied DNA intends to use the net proceeds from this offering
for working capital, capital expenditures, business development and research and development expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The Company also noted
that it intends to resume quarterly earnings conference calls with the report of its 2019 fiscal first quarter results in February
2019. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Applied DNA Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics,
personalized medicine and therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements made by Applied DNA in this press release may
be &quot;forward-looking&quot; in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements
describe Applied DNA's future plans, projections, strategies and expectations, and are based on assumptions and involve a number
of risks and uncertainties, many of which are beyond the control of Applied DNA including the substantial doubt relating to the
Company&rsquo;s ability to continue as a going concern. Actual results could differ materially from those projected due to its
history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development,
future clinical data and analysis, including whether any of Applied DNA&rsquo;s product candidates will advance further in preclinical
research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign
regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S.
FDA or equivalent foreign regulatory agencies, shifting enforcement priorities of US federal laws relating to cannabis, and various
other factors detailed from time to time in Applied DNA's SEC reports and filings, including our Annual Report on Form 10-K filed
on December 18, 2018 and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation
to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to
reflect the occurrence of unanticipated events, unless otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #0070C0"><B>Investor contact: </B></FONT>Sanjay
M. Hurry, 212-838-3777, LHA Investor Relations, <FONT STYLE="color: #0070C0"><B>shurry@lhai.com</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #0070C0"><B>Web:</B></FONT> www.adnas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #0070C0"><B>Twitter: </B></FONT>@APDN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G 0$# 2(  A$! Q$!_\0
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M_P :*Y^6G_-^'_!-^:?\OX_\ Z&BBBLS0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K!\9ZQ?:!X3OM3TZWCGN(%!"RG"@
M9 +'D9P#G%%% 'E,.C?$GQ_"LU[J2V>G2C('FA$(_P!R/)/_  (UV'AWX.^'
MM'*3:AOU2Y7G]\-L0/L@Z_B3110!Z$D:11K'&BHBC"JHP /0"G444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
